ArticleMicrobiology spectrum2025
Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pneumonia after Solid Organ Transplantation.Seminars in respiratory and critical care medicine · 2026Review
- A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Kidney transplant recipients (KTRs) are at high risk for severe influenza and its complications. The effectiveness of baloxavir marboxil (hereafter baloxavir) in infected KTRs is still unknown. In this multicenter retrospective study conducted at eight Grade IIIA hospitals in China, KTRs diagnosed with influenza between October 2023 and March 2024 were enrolled. Of the 246 patients assessed, 117 met the inclusion criteria. There were 59 patients who received baloxavir and 58 patients who received oseltamivir. Patients receiving baloxavir had a longer time from symptom onset to treatment (≤48 h, 59.3% versus 79.3%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.